Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 629

1.

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.

Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.

Transplantation. 2010 Apr 15;89(7):864-72. doi: 10.1097/TP.0b013e3181cbac2d.

PMID:
20061999
2.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group..

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
3.

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.

Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.

Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.

4.

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.

De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.

Liver Transpl. 2009 Oct;15(10):1262-9. doi: 10.1002/lt.21827.

5.

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ; ASCERTAIN Investigators..

Transplantation. 2011 Aug 27;92(4):410-8. doi: 10.1097/TP.0b013e318224c12d. Erratum in: Transplantation. 2011 Nov 27;92(10):e61. multiple investigator names added..

PMID:
21697773
6.

Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.

Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L.

J Heart Lung Transplant. 2012 Mar;31(3):259-65. doi: 10.1016/j.healun.2011.12.010.

PMID:
22333403
7.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

8.

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.

Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.

Liver Transpl. 2003 Oct;9(10):1079-85.

9.

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.

Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.

Transplant Proc. 2009 Dec;41(10):4138-46. doi: 10.1016/j.transproceed.2009.08.065.

PMID:
20005355
10.

Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.

Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group..

J Heart Lung Transplant. 2008 Feb;27(2):197-202. doi: 10.1016/j.healun.2007.11.565.

PMID:
18267227
11.

Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study.

Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group (CAnadian Pilot Sutdy to Determine Safe and Effective Dosing of Neoral and CErtican in Stable Cardiac Transplant Recipients)..

Transpl Int. 2010 Jan;23(1):31-7.

PMID:
20050127
12.

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J; RAD A2420 Study Group..

Transplantation. 2009 Jul 15;88(1):69-76. doi: 10.1097/TP.0b013e3181aa7d87.

PMID:
19584683
13.

Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.

Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK.

J Heart Lung Transplant. 2010 Jun;29(6):641-7. doi: 10.1016/j.healun.2010.01.005. Epub 2010 Mar 20.

PMID:
20304681
14.

Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.

Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.

Clin Transplant. 2009 Jun-Jul;23(3):351-60. doi: 10.1111/j.1399-0012.2009.00963.x. Epub 2009 Feb 5.

PMID:
19208105
15.

Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.

Engelen MA, Amler S, Welp H, Vahlhaus C, Gunia S, Sindermann JR, Rothenburger M, Stypmann J.

Transplantation. 2011 May 27;91(10):1159-65. doi: 10.1097/TP.0b013e31821774bd.

PMID:
21478817
16.

Conversion to everolimus in kidney transplant recipients: to believe or not believe?

Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.

Transplant Proc. 2012 Dec;44(10):2966-70. doi: 10.1016/j.transproceed.2012.06.072.

PMID:
23195007
17.

Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.

DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.

Liver Transpl. 2008 May;14(5):651-9. doi: 10.1002/lt.21429.

18.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
19.

What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?

Hanto DW, Chudzinski R.

Transplantation. 2009 Jan 27;87(2):164-5. doi: 10.1097/TP.0b013e318192790f. No abstract available.

PMID:
19155968
20.

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.

J Heart Lung Transplant. 2005 Dec;24(12):2129-36.

PMID:
16364861

Supplemental Content

Support Center